PaxMedica responds to emergency request for IV suramin

PaxMedica expects to take immediate action in response to an urgent request for IV suramin from the Ministry of Health of Malawi, a country in east Africa. The request seeks emergency access to the Company’s recently completed registration batches of PAX-101 to address the critical shortage of medications required to combat the life-threatening sleeping sickness, also known as Trypanosoma brucei rhodesiense, Human African trypanosomiasis, crisis in the region. Howard Weisman, Chairman and CEO of PaxMedica, emphasized the Company’s dedication to providing immediate assistance in light of the urgent situation, stating: “The emergency request from the Ministry of Health of Malawi underscores the critical need for IV suramin to combat the continued devastating impact of sleeping sickness in the region. PaxMedica has worked with the physicians and the government in Malawi and neighboring countries as part of the ongoing work towards a future NDA submission for PAX-101 in the treatment of TBr HAT. Despite our current limited resources, we plan to help by providing access to PAX-101 in the next 30 days, so that these physicians can continue to use the current standard of care to treat this fatal disease. PaxMedica has worked diligently for many years to ensure access to this life-saving medication for those in need and today’s response to an urgent crisis strongly demonstrates our commitment to this mission.”